Screener
Monte Rosa Therapeutics, Inc. GLUE Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -633%— | -345.2%— | -43.8%— | —— | —— | |
| Net margin | -560.8%— | -302.6%— | -31.2%— | —— | —— | |
| Returns | ||||||
| Return on equity | -42.7%— | -32.6%— | -16.9%— | —— | —— | |
| Return on invested capital | -53.9%— | -46.4%— | -59%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.5× | 0.1×-0.4× | 0.3×+0.1× | 0.5×+0.4× | 0.5×+0.5× | |
| Liquidity | ||||||
| Current ratio | 10.6×+3.4× | 9.5×+3.9× | 6.1×+3.7× | 6.5×+0.5× | 7.2×+0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Per Share | ||||||
| Book value per share | $4.80+47.2% | $5.23+57.5% | $2.81-7.0% | $2.98+19.1% | $3.26+3.4% | |
| Valuation | ||||||
| Market capitalization | $1.33B+395% | $1.32B+361% | $1.02B+139% | $457.64M+5.3% | $291.56M+9.4% | |
| Price / sales | 46.2×+44.7× | 30.6×+28.9× | 8.3×+2.6× | 2.5×-26.5× | 1.6×-44.6× | |
| Price / book | 2.7×+1.7× | 2.5×+1.5× | 4.4×+2.5× | 1.9×-0.3× | 1.1×-0.1× |
FAQ
- Where do Monte Rosa Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Monte Rosa Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
